A&G Pharmaceutical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.agpharma.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
14
NMPA:14
Drug Approvals
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- 国药准字HJ20140588
- Approval Date
- Jun 28, 2024
NMPA
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- 国药准字HJ20140590
- Approval Date
- Jun 28, 2024
NMPA
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- 国药准字HJ20140589
- Approval Date
- Jun 28, 2024
NMPA
Calcium Carbonate and Vitamin D3 Granules
- Product Name
- 小儿碳酸钙D3颗粒
- Approval Number
- 国药准字HJ20130394
- Approval Date
- Nov 15, 2023
NMPA
Calcium Carbonate and Vitamin D3 Granules
- Product Name
- 小儿碳酸钙D3颗粒
- Approval Number
- 国药准字HJ20130395
- Approval Date
- Nov 15, 2023
NMPA
Calcium Carbonate and Vitamin D3 Granules
- Product Name
- 小儿碳酸钙D3颗粒
- Approval Number
- 国药准字HJ20130396
- Approval Date
- Nov 15, 2023
NMPA
Calcium Supplement with Vitamin D Chewable Tablets
- Product Name
- 迪巧
- Approval Number
- J20140154
- Approval Date
- Nov 21, 2019
NMPA
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- H20140588
- Approval Date
- Sep 23, 2019
NMPA
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- H20140590
- Approval Date
- Sep 23, 2019
NMPA
Calcium Carbonate and Vitamin D3 Chewable Tablets (III)
- Product Name
- 迪巧
- Approval Number
- H20140589
- Approval Date
- Sep 23, 2019
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Hormone-Resistant Breast CancerNon Small Cell Lung CancerTriple Negative Breast CancerMesothelioma
- Interventions
- Drug: AG-01 Compound
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- A&G Pharmaceutical Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT05627960
- Locations
- 🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
News
No news found